Biopharmaceutical corporation Celltrion announced on the 29th that it has selected companies for the '2025 Seoul Biohub - Open Innovation Program' Phase 3 aimed at creating a bio-circular ecosystem and has launched full-scale activities.
This program is a project that selects and supports bio and medical startups with innovative technologies and research results for new businesses by Celltrion. The goal is to support the technological advancement of promising startups and establish Celltrion as an anchor corporation contributing to the activation of the bio ecosystem.
The startups selected after approximately two months of evaluation since May are a total of four companies: MustBio, TerraZin, Galux, and PortRay. They possess innovative technologies necessary for next-generation drug development in areas such as ▲ Immunotherapy (MustBio) ▲ Antibody design (TerraZin) ▲ AI drug design (Galux) ▲ Spatial transcriptomics-based pharmacokinetic platform (PortRay).
A representative from Celltrion stated, "The companies selected in this Phase 3 possess high growth potential based on their innovative technologies," adding, "We will systematically support the selected companies so they can achieve their target outcomes and lead the continuous growth of the bio ecosystem."
Meanwhile, Phase 1 selected company EnteroBiome won at '2024KLSAP' as the first Korean company through the global bio-cluster competition program provided by Celltrion and successfully attracted investments in the 100 billion won range. Phase 2 company Biomi is accelerating drug development based on joint research and equity investment agreements with Celltrion.